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Abstract
Mutations in the PINK1 gene cause autosomal recessive familial Parkinson’s disease (PD). The gene encodes a mitochondrial
protein kinase that plays an important role in maintaining mitochondrial function and integrity. However, the
pathophysiological link between mutation-related bioenergetic deficits and the degenerative process in dopaminergic
neurons remains to be elucidated. We performed phosphorous (
31P) and proton (
1H) 3-T magnetic resonance spectroscopic
imaging (MRSI) in 11 members of a German family with hereditary PD due to PINK1 mutations (PARK6) compared to 23 age-
matched controls. All family members had prior 18-Fluorodopa (FDOPA) positron emission tomography (PET). The striatal
FDOPA uptake was correlated with quantified metabolic brain mapping in MRSI. At group level, the heterozygous PINK1
mutation carriers did not show any MRSI abnormalities relative to controls. In contrast, homozygous individuals with
manifest PD had putaminal GPC, PCr, HEP and b-ATP levels well above the 2SD range of controls. Across all subjects, the
FDOPA Ki values correlated positively with MI (r=0.879, p,0.001) and inversely with b-ATP (r=20.784, p=0.008) and GPC
concentrations (r=20.651, p=0.030) in the putamen. Our combined imaging data suggest that the dopaminergic deficit in
this family with PD due to PINK1 mutations relates to osmolyte dysregulation, while the delivery of high energy phosphates
was preserved. Our results corroborate the hypothesis that PINK1 mutations result in reduced neuronal survival, most likely
due to impaired cellular stress resistance.
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Introduction
Mutations of the PTEN-induced putative kinase 1 (PINK1) gene
mapped to chromosome 1p36 (PARK6) were reported in up to
5% of patients with autosomal recessive Parkinson’s disease (PD)
[1,2]. PINK1 encodes a mitochondrial serine-threonine kinase,
which is involved in the protection of neurons against cellular
stress conditions [3,4] and in maintaining mitochrondrial function
and morphology [5]. Recent studies on fibroblasts from PD
patients with endogenous expression of mutant PINK1 pointed to
respiratory chain deficiencies and enhanced production of reactive
oxygen species (ROS), but yielded heterogenous data on cellular
ATP levels, activity of respiratory chain enzymes and antioxidant
defense mechanisms [6,7,8,9].
In order to investigate the pathophysiology of PINK1-associated
PD in a large German family with a PINK1 nonsense mutation
(c.1366C.T; p.Q456X), we performed combined phosphorous
(
31P) and proton (
1H) magnetic resonance spectroscopic imaging
(MRSI) on a 3-Tesla scanner in 11 family members who already
had participated in a prior study with 18-Fluorodopa (FDOPA)
positron emission tomography (PET) [10]. The graded severity of
striatal FDOPA loss in this cohort with either a single or two
mutated PINK1 alleles allowed for correlating individual findings
of metabolic brain mapping in MRSI with previously obtained
PET data. We measured adenosine triphosphate (ATP) as the final
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system, the short-term energy store phosphocreatine (PCr), the
glial activity and osmotic status marker myo-inositol (MI), and
phosphomono- (PME) and -diesters (PDE) as representative
components of neuronal membranes.
Methods
Standard Protocol Approval, Registration and Patient
Consent
The study was approved by the Ethics Committee of the Faculty
of Medicine at the University of Frankfurt/Main (364/08) in
accordance with the declaration of Helsinki. All participants gave
written informed consent. In a thorough examination by an
experienced neurologist, none of the study subjects had cognitive
dysfunction or dementia which might have compromised their
capacity to agree with participation.
Study Subjects
Eleven members of Family W with PINK1 missense mutations
were included. Two women with homozygous mutations (II.5 and
II.7 of pedigree of family W [10]) had typical levodopa-responsive
PD (patient II.5: age 72 years, disease duration 11 years, Unified
Parkinson’s disease Rating Scale (UPDRS-III) [11] off- medication
Table 1.
31P MRSI data of the PINK1 study cohort compared to age-matched healthy controls.
controls
(n=23) 95%CI
PINK1 heterozygous
(n=9) 95%CI
PINK1 homozygous
patient II.5
PINK1
homozygous=patient
II.7
PEth [mmol/l] mesencephalon 1.12 (0.17) 1.05–1.21 1.10 (0.13) 0.94–1.27 1.38 1.46
putamen 1.04 (0.09) 1.00–1.07 0.97 (0.11) 0.89–1.06 1.20 1.18
GPE [mmol/l] mesencephalon 1.40 (0.28) 1.27–1.55 1.57 (0.26) 1.32–1.88 1.62 1.88
putamen 1.31 (0.16) 1.25–1.38 1.30 (0.15) 1.19–1.42 1.78* 2.02*
GPC [mmol/l] mesencephalon 1.44 (0.17) 1.38–1.54 1.47 (0.12) 1.32–1.62 1.60 2.02
putamen 1.54 (0.10) 1.49–1.59 1.54 (0.08) 1.48–1.59 1.85* 1.75*
PCr [mmol/l] mesencephalon 3.22 (0.35) 3.08–3.41 3.20 (0.26) 2.99–3.43 3.25 3.75
putamen 2.99 (0.19) 2.91–3.08 2.85 (0.24) 2.66–3.04 3.49* 3.38*
b-ATP [mmol/l] mesencephalon 1.24 (0.29) 1.11–1.40 1.23 (0.16) 1.02–1.43 1.82 1.42
putamen 1.79 (0.20) 1.69–1.88 1.66 (0.12) 1.57–1.76 2.01 2.22*
Pi [mmol/l] mesencephalon 1.08 (0.16) 1.01–1.17 0.94 (0.19) 0.84–1.09 0.85 1.38
putamen 1.08 (0.13) 1.02–1.13 0.96 (0.11) 0.87–1.05 1.15 1.13
PCho [mmol/l] mesencephalon 0.19 (0.07) 0.17–0.22 0.21 (0.03) 0.17–0.24 0.11 0.25
putamen 0.17 (0.04) 0.16–0.19 0.15 (0.04) 0.12–0.18 0.16 0.26*
HEP [mmol/l] mesencephalon 4.46 (0.44) 4.28–4.71 4.43 (0.27) 4.21–4.66 5.07 5.17
putamen 4.78 (0.36) 4.63–4.94 4.52 (0.29) 4.29–4.74 5.50* 5.60*
LEP [mmol/l] mesencephalon 5.47 (1.14) 4.93–6.00 5.28 (1.26) 4.96–6.60 3.72 4.20
putamen 7.44 (0.69) 7.14–7.74 7.61 (1.06) 6.79–8.42 6.01* 6.36
Data are given as mean (1SD). 95% CI=95% confidence interval. Bold data with an asterisk mark values outside of the 2SD range of controls.
doi:10.1371/journal.pone.0051308.t001
Table 2.
1H MRSI data of the PINK1 study cohort compared to age-matched healthy controls.
controls
(n=23) 95%CI
PINK1 heterozygous
(n=9) 95%CI
PINK1 homozygous
patient II.5
PINK1 homozygous
patient II.7
MI [mmol/l] mesencephalon 7.25 (1.10) 6.73–7.77 7.57 (0.97) 6.32–8.10 5.29 5.97
putamen 7.38 (0.94) 6.98–7.79 7.50 (0.85) 6.85–8.15 5.66 6.23
tCho [mmol/l] mesencephalon 2.93 (0.42) 2.72–3.13 2.79 (0.38) 2.36–3.24 2.46 2.38
putamen 2.98 (0.37) 2.82–3.13 3.00 (0.41) 2.69–3.32 2.89 2.97
tCre [mmol/l] mesencephalon 7.60 (1.02) 7.12–8.08 7.33 (1.07) 6.27–8.74 6.11 6.57
putamen 9.31 (0.70) 9.01–9.61 9.45 (1.00) 8.68–10.21 7.98 8.56
NAA [mmol/l] mesencephalon 14.96 (1.83) 14.11–15.82 13.71 (2.04) 11.55–16.45 13.48 13.39
putamen 13.95 (1.26) 13.40–14.50 13.20 (1.11) 12.33–14.05 11.96 12.78
Glx [mmol/l] mesencephalon 9.59 (3.45) 7.97–11.20 10.21 (1.76) 7.95–12.07 12.42 12.18
putamen 11.28 (1.78) 10.51–12.04 11.64 (1.35) 10.60–12.68 8.36 8.45
Data are given as mean (1SD). 95% CI=95% confidence interval.
doi:10.1371/journal.pone.0051308.t002
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disease duration 12 years, UPDRS III off-medication 21, HY II).
Nine heterozygous mutation carriers (7 men, 2 women, mean age
47.166.0 years) also participated. Of these, seven had mild
bradykinesia, resting tremor or reduced arm swing during walking
(mean UPDRS III medication-off 464), two men presented
without clinical signs. All study participants had undergone
FDOPA-PET 30 months prior to MRSI whose results were
published in a recent paper [10]. However, two family members
with homozygous PINK1 mutations who also attended the PET
study were not able to take part in the current MRSI study.
Twenty-three age- and gender-matched healthy individuals (6
men, 17 women; mean age 46.069.6 years) without neurological,
psychiatric or systemic disease served as control group for MRSI.
FDOPA Positron Emission Tomography (PET)
FDOPA-PET scans were performed at the Max-Planck Institute
for Neurological Research, Cologne, Germany according to
standard methods published recently [10].
Magnetic Resonance Spectroscopy Imaging (MRSI)
MRSI was undertaken at the Brain Imaging Center of Goethe
University Frankfurt/Main on a 3 Tesla whole-body system
(Magnetom Trio, Siemens Medical AG, Erlangen, Germany) with
a double-tuned
1H/
31P volume head coil (Rapid Biomedical,
Wu ¨rzburg, Germany). A combination of point resolved selective
spectroscopy and outer volume suppression was used to select
volumes-of-interest in
1H MRSI (TR 1500 ms, TE 30 ms, 2
acquisitions, 2406240 mm
2 FOV). We obtained midbrain 2D
1H
MRSI by a coronal slice aligned to the dorsal border of the
pontine and midbrain tegmentum (28628 matrix extrapolated to
48648, 10 mm slice thickness). A second axial
1H MRSI covered
the putamen (16616 matrix extrapolated to 32632; 12 mm slice
thickness) [13]. Proton decoupling during
31P data acquisition (TR
2000 ms, TE 2.3 ms, 10 acquisitions, flip angle of 60u,1 0 61068
matrix extrapolated to 20620616, 30063006200 mm
3 FOV)
was achieved by wideband alternating phase low power technique
for zero residual splitting (WALTZ4).
MRSI Data Processing
Partial volume effects originating from the cerebrospinal fluid
were taken into account by the fraction of grey and white matter
taken from isotropic T1 weighted 3D images of the total brain
[14]. These were aligned to the MRSI slab followed by digital
filtering to mimic the effect of poor point spread function and
resolution caused by the limited number of phase encoding steps.
[15] The protocol was previously described in detail [13]. The
resulting parameter maps provided values for the partial volume of
grey and white matter for each voxel.
1H MRSI spectra were fitted
with the software tool LC Model (Provencher, http://s-
provencher.com). Baseline correction was performed including
macromolecules.
31P spectra were analyzed in the time domain
with the jMRUI software tool (Version 3.0, http://www.mrui.uab.
es) employing a non-linear least square fitting algorithm
(AMARES). Absolute concentrations were calculated by referring
to independent measurements with a spherical phantom contain-
ing a solution of 100 mmol/l acetate as calibration standard for
1H data (TR=10 s) and 20 mmol/l phosphate for
31P data
(TR=60 s). For both phantoms, coil loading was within the 20%
range of those used in patient scans. Corrections for T1 and T2
relaxations were performed as described previously [13,16]. T2
correction was not performed for
31P data. Volume concentrations
were converted into tissue concentrations by division with the
tissue fraction (sum of grey and white matter), i.e. assuming no
metabolites in the CSF fraction.
31P MRSI Metabolites
The phosphomonoesters phosphocholine (PCho) and phos-
phoethanolamine (PEth) are precursors of neuronal membrane
lipids, whereas the phosphodiesters glycerophosphocholine (GPC)
and glycerophosphoethanolamine (GPE) represent membrane
lipid catabolites. Hence, the relation of these metabolites provides
information on the balance between membrane constitution and
degradation. ATP is the end product of oxidative phosphorylation.
ATP exhibits 3 signals according to the a-(7.5 ppm,) b-(16.5 ppm),
and c-(2.5 ppm) phosphate group. While the a-and c-signals
coincide with the a-and b-signals from ADP, the b-ATP signal is
specific for ATP and its intensity can be considered as a marker for
total ATP concentration. Conversion of phosphocreatine (PCr) to
creatine (Cre) and inorganic phosphate (Pi) via the creatine kinase
reaction represents the most important short term energy buffer of
high-energy phosphates (HEP).
1H MRSI Metabolites
Pooled choline-containing compounds (tCho) are a marker for
membrane related processes. tCho represents the sum of the
phosphorylated compounds PCho and GPC and an additional
choline fraction which cannot be detected by
31P MRS (rCho). N-
acetyl-aspartate (NAA) is formed in neuronal mitochondria and
also considered as a marker of mitochondrial integrity and
function in neurons. Pooled creatine compounds (tCre) represent
the sum of unphosphorylated Cr and phosphocreatine (PCr). The
signal pattern Glx is attributed to the sum of glutamate (Glu) and
glutamine (Gln) signals. Glutamate is the most important
Table 3. Calculated MRSI data of the PINK1 study cohort compared to age-matched healthy controls.
controls
(n=23) 95%CI
PINK1
heterozygous
(n=9) 95%CI
PINK1
homozygous
patient II.5
PINK1
homozygous
patient II.7
rCho [mmol/l] mesencephalon 0.39 (0.34) 0.24–0.55 0.31 (0.28) 0.03–0.60 0.008 0.001
putamen 0.37 (0.28) 0.25–0.49 0.42 (0.29) 0.19–0.64 0.013 0.067
Cre [mmol/l] mesencephalon 2.08 (0.89) 1.66–2.49 1.97 (0.75) 1.20–2.88 1.03 0.84
putamen 3.52 (0.47) 3.32–3.72 3.76 (0.74) 3.19–4.33 2.09* 2.61
ADP [mmol/l] mesencephalon 0.02 (0.01) 0.02–0.03 0.19 (0.01) 0.01–0.03 0.14 0.008
putamen 0.05 (0.01) 0.05–0.06 0.06 (0.01) 0.05–0.07 0.03* 0.04
Data are given as mean (1SD). 95% CI=95% confidence interval. Bold data with an asterisk mark values outside of the 2SD range of controls.
doi:10.1371/journal.pone.0051308.t003
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regarded to be a glial marker serving as an important osmolyte in
regulating the cell volume of astrocytes.
Calculated Parameters
ADP and Cr levels were calculated from the local tissue
concentrations. The residual signal resonating at 3.2 ppm in the
1H spectra was calculated as:
[rCho]=[tCho] – ([PCho]+[GPC]).
Further calculations were made for:
High-energy phosphates: [HEP]=[b-ATP]+[PCr].
Low-energy metabolites: [LEP]=[ADP]+([tCr] 2 [PCr])+[Pi].
Statistics
Statistical analysis was performed with STATISTICA (version
7.1, StatSoft, Tulsa, OK, USA) and SPSS 19.0 for Windows (IBM,
Chicago, IL, USA, Error! Hyperlink reference not valid.
MRSI metabolites and FDOPA Ki, values were averaged for both
cerebral hemispheres. We tested for between-group differences
using the non-parametric Mann-Whitney-U-Test. Moreover, we
calculated Spearman rank correlation of FDOPA Ki and MRSI
data. For all tests, the significance threshold was set at p,0.05
(two-tailed).
Results
FDOPA PET
The mean FDOPA Ki values of the nine heterozygous mutation
carriers were 0.010360.0023 min
21 (caudate),
0.010060.0023 min
21 (entire putamen), 0.010460.0023 min
21
(anterior putamen) and 0.009460.0023 min
21 (posterior puta-
men). Both homozygous PD patients (II.5 and II.7 of pedigree of
family W [10]) had severely reduced FDOPA Ki levels:
0.0090 min
21 and 0.0057 min
21 (caudate), 0.0051 min
21 and
0.0058 min
21 (entire putamen), 0.0070 min
21 and 0.0072 min
21
(anterior putamen), and 0.0036 min
21 and 0.0046 min
21 (poste-
rior putamen). For comparison, reference Ki data of healthy
controls obtained in our PET laboratory [10] amount to
0.012260.0014 min
21 (caudate), 0.012760.0014 min
21 (entire
putamen), 0.013260.0013 min
21 (anterior putamen) and
0.012360.0015 min
21 (posterior putamen).
MRSI
MRSI did not reveal any significant mean differences between
heterozygous PINK1 mutation carrriers and age-matched controls
(Tables 1–3). Both homozygous women with clinically manifest
PD had putaminal peak levels of the membrane catabolites GPC
and GPE and of the bioenergy marker HEP above the controls’
2SD range (Table 1). With respect to single HEP components,
patient II.7 revealed both higher b-ATP and PCr, whereas patient
II.5 had higher PCr only. Moreover, patient II.7 showed increased
PCho and patient II.5 decreased LEP, Cre and ADP levels in the
putamen.
Correlation of PET and MRSI Data
Over the entire study cohort (n=11), the mean FDOPA Ki
values correlated positively with MI levels (r=0.879, p,0.001),
and inversely with b-ATP (r=20.784, p=0.008) and GPC
concentrations (r=20.651, p=0.030) in the putamen (Table 4
and Figure 1a–c). Analyzing heterozygote mutation carriers alone
(n=9), appropriate correlations were found for MI and b-ATP,
but not for GPC (Table 4).
Figure 1. Correlation of MRSI and PET findings in the putamen.
Across the entire study cohort with either a single heterozygous (n=9,
open circles) or two homozygous PINK1 mutations (n=2, black
triangles), the mean putaminal FDOPA Ki values (min
21) determined
by PET correlated positively with MRSI-measured MI levels (r=0.879,
p,0.001) (a), but inversely with ATP (r=20.784, p=0.008) (b) and GPC
concentrations (r=20.651, p=0.030) (c). Spearman rank correlation, p-
values give the significance level. The dashed horizontal lines set the
upper and lower limits of the 2SD range in healthy controls. Note that
we found concentrations above the upper limit for GPC in both and for
ATP in one of the homozygous mutation carriers.
doi:10.1371/journal.pone.0051308.g001
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The MRSI findings in heterozygous family members with a
mild dopaminergic dysfunction in FDOPA PET suggest that
heterozygous loss-of-function is associated with a normal
level of high-energy phosphates in mesostriatal brain tissue. In
contrast, two homozygous PINK1 mutation carriers with typical
PD phenotype and severely reduced FDOPA uptake revealed
pathological concentrations of putaminal MRSI metabolites. In
particular, elevated levels of the membrane breakdown product
GPC and of the high energy phosphates PCr and b-ATP were
observed. Across all family members, the putaminal FDOPA Ki
values correlated inversely with b-ATP and GPC levels and
positively with MI concentrations. Our data suggest that
dopaminergic dysfunction in this family with PINK1 mutations
is accompanied by unaffected delivery of high-energy phosphates
and osmolyte dysregulation in the striatum.
PINK1 predominantly localizes to mitochondria [17] indicating
that the protein plays a role in neuronal energy metabolism. It is
also involved in cell signaling and intracellular Ca
2+ homeostasis
[18]. In mammalian cells with PINK1 knockdown, disturbed
energy maintenance with increased ATP consumption has been
found in case of high-energy demand [6,19]. Thus, it has been
argued that PINK1-deficient neurons are unable to adequately
fuel several ATP-demanding processes. However, our in vivo
brain imaging data in family W indicate that either homo- or
heterozygous carriers of a PINK1 mutation do not inevitably
reveal a noticeable depletion of high-energy phosphates in the
striatum. Therefore, it is possible that PINK1 mutations in family
W do not induce relevant changes of the bioenergetic status in
affected neurons. In line with this interpretation, recent in-vitro
studies investigating the impact of PINK1 mutations on mito-
chondrial ATP production did not reveal uniform evidence for the
failure of energy supply in these cells. Whereas the complexes of
the mitochondrial oxidative phosphorylation (OXPHOS) system
(respiratory chain complexes I-IV finally yielding ATP via
complex V) appeared normal in most PINK1-deficient cells
[7,9,18,19], another group reported diminished enzyme activities
[20]. ATP steady-state levels were decreased in fibroblasts with
homozygous PINK1 nonsense mutations (p.Q456X), but unaf-
fected in those harbouring a homozygous missense mutation
(p.V170G) [7].
Unexpectedly, we even found higher putaminal PCr and HEP
levels in both PD patients with homozygous PINK1 mutations
compared to controls. Due to the small number of homozygous
study participants, the conclusions allowed to draw from these
data are surely limited, and it cannot be excluded with certainty
that these findings in two individuals are spurious. However,
considering the strong inverse correlation between striatal
dopaminergic degeneration and b-ATP levels over the entire
study cohort, we alternatively hypothesize that the increased levels
of high-energy phosphates in homozygous PINK1 are accom-
plished by ATP generation beyond the OXPHOS system, possibly
at the expense of intracellular milieu changes. Some recent in vitro
findings corroborate this hypothesis: While skin fibroblasts of a
patient with a homozygous PINK1 mutation showed lowered ATP
levels in a galactose medium, higher ATP concentrations were
observed in a glucose solution presumably due to enhanced
glycolytic activity [21]. The authors concluded that depressed
OXPHOS activity was counterbalanced by an increased ATP
synthesis via glycolysis potentially inducing a noxious lactate
acidosis. In this regard, it is important to note that in-vivo MRSI
mapping includes the whole brain tissue with neurons and
surrounding neuroglia, which is a key advantage of in-vivo brain
imaging compared to the somewhat artificial study conditions in
isolated cell cultures. Whereas neurons failed to significantly raise
glycolysis after pharmacological blocking of respiration [22], brain
tissue is able to utilize enhanced glycolysis in astrocytes to maintain
mitochondrial respiration and ATP levels in case of increased
energy demand [23]. Astrocytes were shown to participate directly
in transmitter processing, osmotic regulation and in substrate
provision for adjacent neurons [24]. Another line of evidence
suggests that the limitation of mitochondrial OXPHOS substrates
seems to be a key mechanism in PINK1 pathology, which may
result in a switch from production to hydrolysis of ATP to ADP via
complex V [6]. This phenomenon was reversed by adding
respiratory chain substrates pointing to compensatory mechanisms
directed at the maintenance of the mitochondrial membrane
potential and of sufficient ATP levels in PINK1 deficient cells. In
line with this hypothesis, complex II and/or III activity was
elevated in fibroblasts of a further patient with a homozygous
PINK1 missense mutation [7].
Furthermore, we found a close correlation of decreased striatal
MI levels with low FDOPA Ki in the entire study cohort, which
persisted in the putamen when heterozygote family members were
Table 4. Correlation of striatal FDOPA-PET Ki values with selected putaminal MRSI data given for all PINK1 mutation carriers
(n=11) and for individuals with heterozygous mutations only (n=9).
MRSI putamen
MI GPC b-ATP
Homo- and
Heterozygote
individuals
(n=11)
Heterozygote
individuals (n=9)
Homo- and
Heterozygote
individuals
(n=11)
Heterozygote
individuals (n=9)
Homo- and
Heterozygote
individuals
(n=11)
Heterozygote
individuals (n=9)
FDOPA Ki caudate r=,683 p=0,020 n.s. r=2,692 p=0,018 n.s. r=2,747 p=0,008 r=2,686 p=0,041
putamen r=,879 p,0,001 r=,795 p=0,01 r=2,651 p=0,030 n.s. r=2,784 p=0,008 r=2,669 p=0,049
putamen anterior
part
r=,843 p=0,001 r=,762 p=0,017 r=2,738 p=0,010 n.s. r=2,743 p=0,009 n.s.
putamen posterior
part
r=,891 p,0,001 r=,817 p=0,007 n.s. n.s. r=2,773 p=0,005 n.s.
r=Spearman rank correlation coefficient; n.s.=not significant.
doi:10.1371/journal.pone.0051308.t004
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homozygous PINK1 mutation carriers are not skewing the
correlation towards positive in this case, which suggests a true
relationship between putaminal dopamine neuron loss and MI
concentrations. MI is a sugar alcohol with a molecular structure
similar to glucose. The molecule is predominantly found in
astrocytes and, therefore, often interpreted as a gliosis marker [25].
However, MI is also a potent osmoregulator and an intracellular
messenger molecule [26]. Increased cerebral MI concentrations
have been reported in patients with AD and mild cognitive
impairment [27,28]. A previous MRSI study in two siblings with a
homozygous PINK1 mutation outside of the kinase domain found
elevated MI levels in the basal ganglia [29]. In contrast, MI
reductions are more difficult to interpret given the complex
biochemical pathways in which this molecule is involved. The cell
volume of neurons faced with osmotic stress is long-term regulated
by intracellular concentration changes of organic solutes, such as
inositol, betaine and amino acids [30]. In a previous
31P-MRSI
study, oxidative stress with increased ROS concentrations led to
osmotic dysregulation in cultured rat astrocytes, accompanied by
changes of cellular morphology and a long-lasting loss of the MI
peak [31]. Cerebral hyperammonemia in hepatic encephalopathy
is another example for the converse role of osmotically active
solutes: the detoxification of ammonia requires glutamine
production in glial cells, which leads to a strong decrease of MI
to maintain the osmotic intracellular balance [32]. PINK1
deficiency impairs stimulated Ca
2+ uptake in the mitochondria
and leads to intracellular Ca
2+ overload, which increases the
number of ROS with subsequent mitochondria-dependent apop-
tosis [18,19]. Therefore, we hypothesize that our MRSI findings
reflect counterbalancing of intracellular Ca
2+ accumulation by MI
depletion in astrocytes of PINK1 mutation carriers.
Finally, we found another significant inverse correlation
between high GPC and low FDOPA uptake levels over all study
subjects. Freely mobile GPC as an important component of the
PDE peak in proton-decoupled
31P-MRSI is a breakdown product
of phosphatidylcholine and of the phospholipid bilayer of neuronal
membranes [33]. PDE resonance has been shown to increase
linearly in patients with progressive Alzheimer’s disease (AD), but
to decrease with aging in control subjects [34]. Moreover, PDE
levels were strongly correlated with the number of senile plaques in
AD [35]. Therefore, elevated GPC levels in the putamen of our
PINK1 patients and their close correlation with local FDOPA
uptake loss might indicate increased phospholipid peroxidation
and neuronal membrane degradation due to oxidative stress [36].
However, statistical significance disappeared when heterozygote
mutation carriers were analyzed alone suggesting that the positive
finding is mainly driven by the data outliers of the two
homozygous study subjects. Therefore, we believe that the
biological significance of our GPC findings is questionable and
needs validation in further studies. This holds also true for the
small number of individuals with PINK1 mutations who could be
measured with combined MRSI so far.
Taken together, our metabolic brain imaging data provide in-
vivo evidence for preserved energy supply coming along with
osmotic stress in the striatum of PINK1 mutation carriers who had
a clear dopaminergic dysfunction in FDOPA PET. Since
mitochondrial dysfunction presumably constitutes a converging
pathway in patients with different forms of hereditary and sporadic
PD, the reported bioenergetic findings in PINK1 patients may also
be true in sporadic cases, and this question has to be addressed in
future studies.
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